相关实验视频

Updated: Jun 24, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

多尔索摩芬减弱了结直肠癌中ABCG2介导的多药耐药性

Xiao-Peng Li^1,2, Liang-Qi Cao³, Ze-Zhong Yu^1,2

¹Cancer Minimally Invasive Therapies Centre, Guangdong Second Provincial General Hospital, Jinan University, Guangzhou, China.

Frontiers in pharmacology

|June 10, 2024

概括

多尔索摩芬抑制了ABCG2转运体的活性,克服了结直肠癌中化疗耐药性的作用. 这种化合物保留了抗癌药物,为这些瘤的多药耐药性 (MDR) 提供了潜在的策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

结肠直肠癌 (CRC) 是一个重大的全球健康挑战,其特点是高死亡率.
化疗耐药性,特别是多药耐药性 (MDR),是CRC治疗失败的主要驱动因素.
癌细胞中ABCG2载体的过度表达导致化疗剂的流出,从而导致MDR.

研究的目的:

为了研究dorsomorphin作为ABCG2转运器活性抑制剂的潜力.
评估dorsomorphin在克服结直肠癌细胞中ABCG2介导的多药耐药性的疗效.
阐明dorsomorphin与ABCG2相互作用的机制.

主要方法:

基于细胞的测定被用来评估dorsomorphin对ABCG2转运体活性的影响.
评估了多尔索摩芬对化疗剂 (米托克桑,多克索鲁比辛) 细胞内积累的影响.
进行了分子对接研究,以预测dorsomorphin和ABCG2蛋白之间的结合相互作用.

主要成果:

多尔索摩芬强烈抑制了ABCG2.2的输送活性.
多尔索摩芬治疗导致ABCG2过度表达的结肠直肠癌细胞中线粒和多克索鲁的细胞内度增加.
分子对接揭示了dorsomorphin在ABCG2结合口袋中的稳定结合,这表明了直接的抑制机制.
多尔索摩芬没有影响ABCG2.2的总体蛋白质表达水平.

结论:

多尔索摩芬作为ABCG2转运器功能的强有力的抑制剂.
通过抑制ABCG2,dorsomorphin可以恢复结直肠癌细胞对标准化疗剂的敏感性.
多尔索摩芬代表了一种有前途的治疗策略,用于对抗结直肠癌中ABCG2介导的多药耐药性.

关键词:

这就是ABCG2ABCG2.化学敏感性化学敏感性结肠直肠癌是什么意思这是一种dorsomorphin.多种药物耐药性多种药物耐药性

更多相关视频

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Carrier-Mediated Transport

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...